Neurocrine biosciences presents 48-week remission data on treatment of tardive dyskinesia with ingrezza® (valbenazine) capsules

Majority of participants reached a defined threshold for remission of tardive dyskinesia regardless of underlying psychiatric disorder findings presented at the 2025 psychiatry update conference san diego , march 20, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presented new data from the long-term, open-label kinect® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily ingrezza® (valbenazine) capsules. this analysis was presented at the 2025 psychiatry update conference in chicago.
NBIX Ratings Summary
NBIX Quant Ranking